Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older
- Authors
- Cunningham, Anthony L.; Heineman, Thomas C.; Lal, Himal; Godeaux, Olivier; Chlibek, Roman; Hwang, Shinn-Jang; McElhaney, Janet E.; Vesikari, Timo; Andrews, Charles; Choi, Won Suk; Esen, Meral; Ikematsu, Hideyuki; Choma, Martina Kovac; Pauksens, Karlis; Ravault, Stephanie; Salaun, Bruno; Schwarz, Tino F.; Smetana, Jan; Vanden Abeele, Carline; Van den Steen, Peter; Vastiau, Ilse; Weckx, Lily Yin; Levin, Myron J.
- Issue Date
- 1-6월-2018
- Publisher
- OXFORD UNIV PRESS INC
- Keywords
- varicella-zoster virus; herpes zoster vaccine; gE subunit vaccine; adjuvant system; immunogenicity
- Citation
- JOURNAL OF INFECTIOUS DISEASES, v.217, no.11, pp.1750 - 1760
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF INFECTIOUS DISEASES
- Volume
- 217
- Number
- 11
- Start Page
- 1750
- End Page
- 1760
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/74972
- DOI
- 10.1093/infdis/jiy095
- ISSN
- 0022-1899
- Abstract
- Background. The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01(B) Adjuvant System, was highly efficacious in preventing herpes zoster in the ZOE-50 and ZOE-70 trials. We present immunogenicity results from those trials. Methods. Participants (ZOE-50: >= 50; ZOE-70: >= 70 years of age) received 2 doses of HZ/su or placebo, 2 months apart. Serum anti-gE antibodies and CD4 T cells expressing >= 2 of 4 activation markers assessed (CD4(2+)) after stimulation with gE-peptides were measured in subcohorts for humoral (n = 3293) and cell-mediated (n = 466) immunogenicity. Results. After vaccination, 97.8% of HZ/su and 2.0% of placebo recipients showed a humoral response. Geometric mean anti-gE antibody concentrations increased 39.1-fold and 8.3-fold over baseline in HZ/su recipients at 1 and 36 months post-dose 2, respectively. A gE-specific CD4(2+) T-cell response was shown in 93.3% of HZ/su and 0% of placebo recipients. Median CD42+ T-cell frequencies increased 24.6-fold (1 month) and 7.9-fold (36 months) over baseline in HZ/su recipients and remained >= 5.6-fold above baseline in all age groups at 36 months. The proportion of CD4 T cells expressing all 4 activation markers increased over time in all age groups. Conclusions. Most HZ/su recipients developed robust immune responses persisting for 3 years following vaccination.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.